Cancer immunotherapy

Natural killer cells
#allogeneic cell therapies #Cancer immunotherapy #Cancer research #Cancer treatment

Zelluna Immunotherapy secures funding for cancer treatments

Investment from Takeda ventures will fund the development of Zelluna Immunotherapy’s allogeneic T Cell Receptor Natural Killer (TCR-NK) cells for the treatment of cancer. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical Trial Application (CTA) / Investigational New Drug Application (IND) readiness and,… Read More

#Business & Investment #Cancer Research #News

Bladder
#Cancer immunotherapy #Oncology #Regulatory

The avelumab story and what it means for urothelial carcinoma

Listen to this article on the DDW Podcast: Following the announcement that Merck & Pfizer’s immunotherapy drug avelumab has been approved by National Institute for Health and Care Excellence (NICE) in the UK, Lu Rahman speaks to Dr Stuart Hill, Medical Director for Merck, about the development of the drug and… Read More

#Exclusive Content

#Cancer immunotherapy #Immunotherapy #Liver disease #Oncology

Immunotherapy before surgery in liver cancer patients can kill the tumour  

In a clinical trial, Mount Sinai scientists gave immunotherapy to liver cancer patients before they received surgery and found that tumours died off significantly before surgery in a third of the patients, according to results reported in The Lancet Gastroenterology and Hepatology.   The results  The researchers… Read More

#News #Trending News

#Cancer immunotherapy #Collaboration #Drug design #Drug targets #Oncology

Collaboration will investigate next-generation cancer therapies 

PhoreMost, a UK-based biopharmaceutical company developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, have collaborated to study oncology targets currently considered undruggable.   The agreement  The POLARISqb Tachyon quantum computing platform will be used to scan billions of… Read More

#News

#Cancer immunotherapy #Cancer research #Immunotherapy #Tumour

New immunotherapy insights for kidney cancer 

Researchers at the Francis Crick Institute, The Royal Marsden NHS Foundation Trust and UCL have found immune cell patterns within tumours that can help predict if patients with kidney cancer will respond to immunotherapy.  Clear cell renal cell carcinoma is the most common type of kidney cancer, accounting for… Read More

#News

#Cancer immunotherapy #Flow Cytometry #Immuno-oncology #Webinar

Free webinar addresses bottlenecks in immuno-oncology therapies 

Within our drug discovery world, unless we have contact with clinical settings, it is easy to lose sight that our expertise, time, laboratory instruments, software, reagents, tools, workflows and procedures etc. are ultimately designed for the benefit of real-life patients.  Deriving Context from Immunological Data with Advanced Flow Cytometry… Read More

#News

#Biologics / Biotechnology #Cancer immunotherapy #Drug discovery #Flow Cytometry #Immuno-oncology #Webinar

Webinar offers insight into pharmacological reactions

Dr Nina Senutovitch, Senior Scientist, Sartorius, notes that more efficient and powerful tools are critical for furthering the development of highly target-specific immunotherapies, such as adoptive cell transfer therapies. These include Chimeric Antigen Receptor T cells (CAR-T), that harness an individual’s own immune system to attack cancerous cells. … Read More

#News #Trending News

#Cancer immunotherapy #Funding #Immunology #Precision medicine #Tumour biology

Researchers receive $4 million for exceptional junior scientists

Two Mount Sinai cancer researchers will receive $4 million from the National Institutes of Health (NIH) Common Fund, which supports research by junior scientists around the United States. This will fund radiation oncology and CAR T cell cancer therapy research.  Deborah Marshall, Assistant Professor of Radiation Oncology at The Tisch… Read More

#News

#Biologics / Biotechnology #Cancer immunotherapy #Drug discovery #Flow Cytometry #Immuno-oncology #Webinar

Are you investigating pharmacological reactions?

Dr Nina Senutovitch, Senior Scientist, Sartorius, notes that more efficient and powerful tools are critical for furthering the development of highly target-specific immunotherapies, such as adoptive cell transfer therapies. These include Chimeric Antigen Receptor T cells (CAR-T), that harness an individual’s own immune system to attack cancerous cells. … Read More

#News

#Cancer immunotherapy #Flow Cytometry #Immuno-oncology #Webinar

Addressing bottlenecks in immuno-oncology therapies 

Within our drug discovery world, unless we have contact with clinical settings, it is easy to lose sight that our expertise, time, laboratory instruments, software, reagents, tools, workflows and procedures etc. are ultimately designed for the benefit of real-life patients.  On 4 November 2021, 9AM PT; 12PM ET; 4PM… Read More

#News

#Cancer immunotherapy #Lead optimisation #Pharmaceuticals #Radiology

Collaboration offers therapeutic developments in nuclear medicine 

Oncodesign, Covalab, CheMatech and ABX-CRO have partnered to launch the DRIVE-MRT (Molecular RadioTherapy) solution. Designed to offer therapeutic development in nuclear medicine, this encompasses theranostics, from therapeutic target validation, radiolabeled biological vector generation, lead optimisation, preclinical candidate drug generation and IND, to the design and management of clinical trials.  DRIVE-MRT is based on… Read More

#News

#Cancer immunotherapy #Cancer research #Drug discovery #Immuno-oncology #Systems biology #Therapeutics #Webinar

Event examines emerging strategy for cancer therapeutic development 

In this free webinar, supported by Cell Signaling Technology (CST) and hosted by DDW, Dr. Nathanael Gray, Professor of Chemical and Systems Biology at the Stanford Cancer Institute, will discuss an emerging strategy for cancer therapeutic development – targeted protein degradation (TPD).  Challenges and Opportunities in Protein Degradation, took place on… Read More

#News

#Cancer #Cancer immunotherapy #Cancer research #Clinical trials #Tumour biology

Cancer Awareness Month: Round up 

September 2021 has been Cancer Awareness Month for Blood, Childhood, Gynaecologic, Ovarian and Prostate Cancer, which affect millions of people around the world annually. Here is a round-up of eight of some of the innovative research and studies being done in order to tackle these various types of cancer. … Read More

#Cancer Research #News

#Cancer immunotherapy #Cancer research #Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Can Covid-19 vaccine technology be used for cancer vaccines?

Scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the Oxford-AstraZeneca vaccine for SARS-CoV-2 to develop a vaccine to treat cancer.   Researchers have designed a two-dose therapeutic cancer vaccine using Oxford’s viral vector vaccine technology. When tested in mouse tumour models, the… Read More

#Cancer Research #Covid-19 #Editor's Choice #News